Investors looking to bolster their portfolio with some blue chip ASX 200 shares might want to take a look at the three listed below.
Here's why these blue chips are highly rated:
CSL Limited (ASX: CSL)
The first blue chip ASX share to consider is CSL. It is one of the world's leading biotechnology companies, comprising two businesses – CSL Behring and Seqirus. CSL Behring is the number one player in a global plasma therapies industry worth a massive US$30 billion per year. Whereas Seqirus is the number two player in the US$6 billion global influenza vaccines industry. CSL has been tipped for solid long term growth thanks to increasing demand for its therapies and its lucrative R&D pipeline.
UBS is positive on CSL. It currently has a buy rating and $330.00 price target on its shares.
NEXTDC Ltd (ASX: NXT)
Another blue chip share to look at is NEXTDC. It is a leading data centre operator with world class operations across key Australian location. It has also recently opened offices in Singapore and Tokyo, with a view to expanding into these markets. If this expansion is a success, it could give it a very long runway for growth over the next decade. Particularly given the increasing demand for data centre services due to the structural shift to the cloud.
Goldman Sachs is a big fan. This morning it reiterated its conviction buy rating and $14.80 price target on its shares.
SEEK Limited (ASX: SEK)
A final blue chip ASX share to consider is this job listings giant. It could be a great long term investment option thanks to its investments in growth opportunities and its domination of the ANZ market. The latter is a big positive given Australia's strong economic recovery from the pandemic. With unemployment levels tipped to reduce materially over the next few years, job ad volumes are tipped to rise strongly.
Macquarie recently upgraded the company's shares to an outperform rating with a $40.00 price target.
